Atlas Trials

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Clinical trial NCT02899793 · COMPLETED

Trial details

NCT number
NCT02899793
Sponsor
Yale University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Endometrial Cancer
Start date
2016-09-01
Primary completion
2024-07-17
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.